Sriveda Boyalakuntla, Riten Kumar
Dec 14, 2025, 12:56
Mentored by Riten Kumar, Sriveda Boyalakuntla Presents Key Research on Infection-Associated Thrombosis at ASH25
Kishore Boyalakuntla, GM and CPO at Re:Build Cadonix, reposted Riten Kumar’s post on LinkedIn:
“Congrats Sriveda Boyalakuntla on the work related to infection associated thrombosis. It is special to be mentored by Riten Kumar and the team at Boston Children’s Hospital.”
Quoting Riten Kumar’s post:
“Last day at ASH25 – interesting subgroup analysis from the RENOVE trial, increased CRNM bleeding with apixaban and aspirin, but not NSAIDs and Sriveda BoyalaKuntla’s excellent presentation on infection associated thrombosis, finished off with trainees – past, present and future!”
Get the latest on Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin